The study will be carried out in partnership with The GOG Foundation and the European Network of Gynaecological Oncological ...

Pāpāmoa retiree Marion Henriksen was meant to be travelling in Germany and Austria with a friend. Instead, she had to cancel ...

Solventum, a global MedTech leader at the forefront of infection prevention innovation, today announced the launch of its Attesttm Super Rapid Vaporized Hydrogen Peroxide (VH2O2) Clear Challenge Pack.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...